

17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645
Fax.: (91-22) 6645 5685



FOR IMMEDIATE RELEASE

Sun Pharma to announce Q2 and H1 2008-09 results on Oct. 25, 2008

Oct. 15, 2008, Mumbai: On October 25, 2008, Sun Pharma will announce results for the second quarter and first half ending September 30, 2008. These results will also be available on the Company website, www.sunpharma.com.

Earnings call (6.30 pm IST, October 25, 2008)

The Company will conduct an hour long call at 6.30 pm IST on October 25, 2008 where senior management will discuss the Company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below five to ten minutes ahead of the scheduled start time. The operator will provide instructions on asking questions before the call. You can also hear the call via an audio webcast, details of which will be announced later on the Company website, www.sunpharma.com. A transcript of this conference call will also be available on the website.

Summary of events

Event	Date and time	Telephone number/ website
Earnings release	Afternoon of October 25, 2008	www.sunpharma.com
Earnings conference call	6.30 pm IST, October 25, 2008	Primary Number : +91 22 6629 0101 Secondary Numbers : +91 22 3065 1010 / +91 22 4039 2525 Via audio webcast, details of which will be made available on www.sunpharma.com .
Replay of conference call	October 25, 2008 to November 6, 2008	India: +91 22 3065 1212. ID: 786742# Via audio webcast playback, details of which will be made available on www.sunpharma.com .

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, and orthopedics. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Uday Baldota
Tel +91 22 6645 5645, Xtn 605
Tel Direct +91 22 66455605
Mobile +91 98670 10529
E mail uday.baldota@sunpharma.com

Mira Desai
Tel +91 22 6645 5645, Xtn 606
Tel Direct +91 22 66455606
Mobile +91 98219 23797
E mail mira.desai@sunpharma.com